Physician profile
Amy T Ananth
NPI 1053601252
$8,490.11
in general payments reported to CMS, 2019-2025
39 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,790 · 2020: $577 · 2021: $408 · 2022: $737 · 2023: $1,282 · 2024: $1,305 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,854 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.95 |
| Education | $124.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.54 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $761.56 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $643.71 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Sun Pharmaceutical Industries INC. | $458.39 | 2019-2025 | Ilumya |
| Pfizer INC. | $445.59 | 2019-2025 | |
| Galderma Laboratories, L.P. | $439.55 | 2019-2025 | Epsolay, Aklief, Twyneo |
| Almirall LLC | $406.65 | 2019-2025 | Klisyri |
| Amgen INC. | $382.83 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $379.38 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $325.36 | 2019-2025 | |
| Hill Dermaceuticals, INC. | $279.78 | 2023-2025 | Tolak |
| Medimetriks Pharmaceuticals, INC. | $278.27 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $272.86 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $251.67 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $225.63 | 2019-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ananth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.